Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease: early-phase trial registry
155 of 312 indexed Alzheimer Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #25 of 28,707 conditions by registered trial count.
312 US clinical trials · 155 currently recruiting · #25 of 28,707 conditions by registered trial count
Alzheimer Disease: 312 US clinical trials tracked, 155 recruiting.
Alzheimer Disease is the subject of 312 registered US clinical trials on ClinicalTrials.gov, 155 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 13 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease
OPEN 155 | RECR 50% | LATE 26 | EARLY 104 | RANK #25 | SPON 13
Volume-matched condition peers
Nearest open-share peer: PTSD (50% recruiting · 155 trials)
Alzheimer Disease lists 155 open slots (50% of 312 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease is recruiting above its size-band peers.
155 of 312 indexed trials (49.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimer Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 13 of 312 trials (4.2%). 178 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 307 trials that report a genuine target (sentinel values excluded). 151 of those (49.2%) plan for fewer than 100 participants.
-
Alzheimer Disease research is mostly interventional.
255 interventional and 57 observational studies make up this index (81.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
312 total, page 5 of 7
Fasting ENHANCE Pilot Study
University of Florida
NCT05732935
Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes
MapHabit
NCT05527405
Study of AV-1959D, an Amyloid Beta Vaccine
Institute for Molecular Medicine
NCT05642429
Does EVOO Induce Gene and Metabolic Changes in Healthy Subjects
Augusta University
NCT05929924
The Use of Memantine for Prevention of Alzheimer's Disease
University of Virginia
NCT05063851
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Alzamend Neuro
NCT05834296
ALSENLITE: Senolytics for Alzheimer's Disease
Mayo Clinic
NCT04785300
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
Vanderbilt University Medical Center
NCT05231798
Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
Massachusetts Institute of Technology
NCT04055376
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
Lexeo Therapeutics
NCT05400330
The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia
Columbia University
NCT05172687
Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support
Indiana University
NCT03323502
A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease: Implementation Phase 2
University of Massachusetts, Worcester
NCT06368115
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Novartis Pharmaceuticals
NCT00506415
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
Indiana University
NCT04520698
Aging Brain Care Virtual Program
Indiana University
NCT06245499
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
Boehringer Ingelheim
NCT02788513
Caregiver Speaks: A Technologically Mediated Storytelling Intervention
Washington University School of Medicine
NCT04103580
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Axsome Therapeutics
NCT04947553
Decisions About Cancer Screening in Alzheimer's Disease
Indiana University
NCT03282097
Information About Alzheimer's Disease for Latinos in New York City
Columbia University
NCT04471779
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
C2N Diagnostics
NCT05477056
Enhanced Quality in Primary Care for Elders With Diabetes and Dementia
NYU Langone Health
NCT03723707
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
OPKO Health
NCT00568776
Study of BHV-4157 in Alzheimer's Disease
Biohaven Pharmaceuticals
NCT03605667
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Eli Lilly and Company
NCT05063539
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
Eli Lilly and Company
NCT03367403
Improving the Recovery and Outcome Every Day After the ICU
Indiana University
NCT03095417
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
Avid Radiopharmaceuticals
NCT03901092
Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease
Jose Gutierrez, MD, MPH
NCT04510168
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
University of California, Berkeley
NCT04206670
A Dyadic Approach for a Remote Physical Activity Intervention in Adults With AD and Their Caregivers
University of Kansas
NCT04102514
Technology and Family Thriving Study
University of California, Santa Barbara
NCT05150990
LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers
Hopeful Aging
NCT05516342
A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research
University of Wisconsin, Madison
NCT05444244
Antipsychotic Discontinuation in Alzheimer's Disease
New York State Psychiatric Institute
NCT00417482
Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects
University of Utah
NCT03466736
Caring Light Project for Family Caregivers
Photozig
NCT04517877
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
EIP Pharma
NCT03402659
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
Adam Brickman
NCT03706261
Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Neil M Rofsky, MD, MHA
NCT04080544
A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®
Corium
NCT02968719
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
Amylyx Pharmaceuticals
NCT03533257
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Eli Lilly and Company
NCT04640077
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
Janssen Research & Development
NCT05307692
Community-based Brain Health Program to Address Dementia Risk
Posit Science Corporation
NCT05529706
Therapeutic Diets in Alzheimer's Disease
University of Kansas Medical Center
NCT03860792
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
Mayo Clinic
NCT04567745
Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
Elizabeth K Rhodus
NCT05202223
Caregiver Study Dr. Phillips
AdventHealth
NCT03653871
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 51 |
| Phase 3 | 18 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease page
312 registered trials, 155 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 155 Alzheimer Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimer Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease condition card totals 312 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.